3,4-Dibenzyloxybenzaldehyde

We are 3,4-Dibenzyloxybenzaldehyde CAS:5447-02-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 5447-02-9
Product Name: 3,4-Dibenzyloxybenzaldehyde
Other Name:
3,4-Dibenzyloxybenzaldehyde
3,4-bis(phenylmethoxy)benzaldehyde
3,4-Bis(benzyloxy)benzaldehyde
 
Density: 1.2±0.1 g/cm3
Boiling Point: 492.4±35.0 °C at 760 mmHg
Melting Point: 91-94 °C (dec.)(lit.)
Molecular Formula: C21H18O3
Molecular Weight: 318.366
Flash Point: 243.9±12.4 °C
Exact Mass: 318.125580
PSA: 35.53000
LogP: 4.92
Vapour Pressure: 0.0±1.2 mmHg at 25°C
Index of Refraction: 1.623
 
Specification
Appearance: Light yellow to yellow powder
Assay: ≥99.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

3,4-Dibenzyloxybenzaldehyde


Related News: China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.6-Hydroxy-2(1H)-3,4-dihydroquinolinone China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.540-63-6 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).2-tiofenotiol CAS:7774-74-5 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).Dr. John K. Westwick, CEO of Resonant, added “Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.

Related Products
Product Name
3-Acetyl-1-propanol View Details
tenofovir hydrate View Details
TRIPHENYLPHOSPHINE DIBROMIDE Cas:1034-39-5 View Details
3-chloro-5-hydroxy-benzonitrile manufacturer 4-methoxy-5-(3-morpholin-4-ylpropoxy)-2-nitrobenzonitrile manufacturer 3-(2-chloroethyl)-1H-benzimidazol-2-one manufacturer Cobalt Carbonate manufacturer 6-bromohex-1-ene manufacturer